孕妇结核感染筛查中血浆干扰素-γ水平与子痫前期的关联
在瑞典产前保健中筛查结核感染的3605名孕妇中,19.4%检出结核感染(MtbI),3.1%诊断为子痫前期(其中1.4%为重度)。MtbI孕妇血浆干扰素-γ水平高于MtbI阴性孕妇。MtbI且干扰素-γ>0.28 IU/mL的孕妇,其子痫前期和重度子痫前期的 odds 均高于MtbI阴性且干扰素-γ<0.28 IU/mL的孕妇。
要点
- MtbI孕妇干扰素-γ中位数0.12 IU/mL,高于MtbI阴性者的0.07 IU/mL(p<0.001)。
- MtbI且干扰素-γ>0.28 IU/mL者子痫前期风险升高(OR 2.79,95%CI 1.52-5.12)。
- MtbI且干扰素-γ>0.28 IU/mL者重度子痫前期风险升高(OR 5.46,95%CI 2.64-11.3)。
核心结论
- 血浆干扰素-γ分泌可能作为MtbI与子痫前期发展之间关联的介质。
研究设计与样本
- 基于瑞典产前保健筛查MtbI的登记队列,纳入3605名来自结核流行国家的孕妇,比较血浆干扰素-γ水平与MtbI状态及子痫前期诊断。
主要发现
- MtbI检出700/3605名(19.4%),子痫前期诊断110名(3.1%),其中重度子痫前期50名(1.4%)。
- MtbI孕妇干扰素-γ中位数0.12 IU/mL(IQR 0.06-0.26),高于MtbI阴性孕妇的0.07 IU/mL(IQR 0.04-0.12),p<0.001。
- MtbI且干扰素-γ>0.28 IU/mL者子痫前期患病率13/159(8.2%),OR 2.79(95%CI 1.52-5.12),p<0.001,对照为MtbI阴性且干扰素-γ<0.28 IU/mL者。
- MtbI且干扰素-γ>0.28 IU/mL者重度子痫前期患病率10/159(6.3%),OR 5.46(95%CI 2.64-11.3),p<0.0001,对照为MtbI阴性且干扰素-γ<0.28 IU/mL者。
- MtbI且干扰素-γ<0.28 IU/mL者及MtbI阴性且干扰素-γ>0.28 IU/mL者,相较于MtbI阴性且干扰素-γ<0.28 IU/mL者,子痫前期或重度子痫前期的 odds 均未升高。
关键数值与推荐
- MtbI定义为QuantiFERON结果阳性且无结核病。
- 干扰素-γ高水平的阈值为>研究人群第90百分位(0.28 IU/mL)。
临床怎么用
- 对于来自结核流行国家且筛查为MtbI的孕妇,可关注血浆干扰素-γ水平以评估子痫前期风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pregnancy can influence immune control of Mycobacterium tuberculosis infection (MtbI). We recently reported an association between MtbI and pregnancy complications, particularly severe preeclampsia, in a registry-based cohort of women originating in tuberculosis-endemic countries screened for MtbI in Swedish antenatal care, implying a potential role of MtbI for the development of preeclampsia. Here, we aimed to investigate the role of plasma interferon-γ secretion as a potential mediator of this interaction. METHODS: Plasma interferon-γ levels were compared with women with MtbI (defined as positive QuantiFERON results in the absence of tuberculosis) and MtbI-negative women regarding any diagnosis of preeclampsia and severe preeclampsia. Odds of preeclampsia and severe preeclampsia were compared with respect to MtbI status and interferon-γ levels >90th percentile in the study population (0.28 IU/mL). RESULTS: MtbI was detected in 700 of 3605 women (19.4%) and preeclampsia was diagnosed in 110 (3.1%), among whom 50 (1.4%) had severe preeclampsia. Women with MtbI had higher interferon-γ levels than MtbI-negative women (median 0.12 IU/mL, interquartile range [IQR], 0.06-0.26 IU/mL; vs. 0.07 IU/mL, IQR 0.04-0.12 IU/mL; p < 0.001). The prevalence of preeclampsia of any grade (13/159, 8.2%, odds ratio [OR], 2.79; 95% CI, 1.52-5.12; p < 0.001) and severe preeclampsia (10/159, 6.3%, OR, 5.46; 95% CI, 2.64-11.3; p < 0.0001) was higher in women with MtbI and interferon-γ levels >0.28 IU/mL, than in MtbI-negative women with interferon-γ levels <0.28 IU/mL. Neither women with MtbI with interferon-γ levels <0.28 IU/mL, nor MtbI-negative women with interferon-γ levels >0.28 IU/mL, had increased odds of preeclampsia or severe preeclampsia compared to MtbI-negative women with interferon-γ levels <0.28 IU/mL. DISCUSSION: These findings suggest that interferon-γ secretion could be involved as a mediator in the association between MtbI and development of preeclampsia.
引用
- Walles J, Winqvist N, Hansson SR, et al. Association between plasma interferon-γ levels and preeclampsia in pregnant women screened for tuberculosis infection. Clin Microbiol Infect. 2025. PMID: 40274232. doi:10.1016/j.cmi.2025.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。